Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:actsOn |
gptkb:GABAA_receptor
|
| gptkbp:canBe |
cognitive enhancement
treatment of anxiety |
| gptkbp:CASNumber |
161832-65-1
|
| gptkbp:chemicalFormula |
C17H18N2O2
|
| gptkbp:class |
benzodiazepine
nootropic |
| gptkbp:developedBy |
gptkb:Lundbeck
|
| gptkbp:drugClass |
positive allosteric modulator of GABAA receptor
|
| gptkbp:hasSMILES |
CC1(C)Oc2ccccc2C1C3=NCCNC4=CC=CC=C34
|
| https://www.w3.org/2000/01/rdf-schema#label |
NS16082
|
| gptkbp:IUPACName |
6-(2,2-dimethyl-2H-1-benzopyran-4-yl)-1,2,4,5-tetrahydro-3H-3-benzazepine-3-one
|
| gptkbp:molecularWeight |
282.34 g/mol
|
| gptkbp:PubChem_CID |
9942222
CHEMBL2103866 |
| gptkbp:synonym |
6-(2,2-dimethyl-2H-1-benzopyran-4-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-one
|
| gptkbp:bfsParent |
gptkb:NT16000_series
|
| gptkbp:bfsLayer |
8
|